Mostrar el registro sencillo

dc.contributor.authorCatalá López, Ferrán
dc.contributor.authorHutton, Brian
dc.contributor.authorDriver, Jane A.
dc.contributor.authorPage, Mathew J.
dc.contributor.authorRidao, Manuel
dc.contributor.authorValderas, José M.
dc.contributor.authorAlonso Arroyo, Adolfo
dc.contributor.authorForés Martos, Jaume
dc.contributor.authorMartínez, Salvador
dc.contributor.authorGènova Maleras, Ricard
dc.contributor.authorMacías Saint Gerons, Diego
dc.contributor.authorCrespo Facorro, Benedicto 
dc.contributor.authorVieta, Eduard
dc.contributor.authorValencia, Alfonso
dc.contributor.authorTabarés Seisdedos, Rafael
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2018-05-11T14:30:08Z
dc.date.available2018-05-11T14:30:08Z
dc.date.issued2017
dc.identifier.issn2046-4053
dc.identifier.urihttp://hdl.handle.net/10902/13686
dc.description.abstractBACKGROUND: The objective of this study will be to synthesize the epidemiological evidence and evaluate the validity of the associations between central nervous system disorders and the risk of developing or dying from cancer. METHODS/DESIGN: We will perform an umbrella review of systematic reviews and conduct updated meta-analyses of observational studies (cohort and case-control) investigating the association between central nervous system disorders and the risk of developing or dying from any cancer or specific types of cancer. Searches involving PubMed/MEDLINE, EMBASE, SCOPUS and Web of Science will be used to identify systematic reviews and meta-analyses of observational studies. In addition, online databases will be checked for observational studies published outside the time frames of previous reviews. Eligible central nervous system disorders will be Alzheimer's disease, anorexia nervosa, amyotrophic lateral sclerosis, autism spectrum disorders, bipolar disorder, depression, Down's syndrome, epilepsy, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia. The primary outcomes will be cancer incidence and cancer mortality in association with a central nervous system disorder. Secondary outcome measures will be site-specific cancer incidence and mortality, respectively. Two reviewers will independently screen references identified by the literature search, as well as potentially relevant full-text articles. Data will be abstracted, and study quality/risk of bias will be appraised by two reviewers independently. Conflicts at all levels of screening and abstraction will be resolved through discussion. Random-effects meta-analyses of primary observational studies will be conducted where appropriate. Parameters for exploring statistical heterogeneity are pre-specified. The World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) criteria and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used for determining the quality of evidence for cancer outcomes. DISCUSSION: Our study will establish the extent of the epidemiological evidence underlying the associations between central nervous system disorders and cancer and will provide a rigorous and updated synthesis of a range of important site-specific cancer outcomes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42016052762.es_ES
dc.description.sponsorshipFunding: Specific funding from the Generalitat Valenciana (PROMETEOII/2015/021) and CIBERSAM/Institute of Health Carlos III was received for this work. The funders were not involved in the design of the protocol or decision to submit the protocol for publication nor will they be involved in any aspect of the conduct of the review. BH is supported by a New Investigator Award from the Canadian Institutes of Health Research and the Drug Safety and Effectiveness Network. MJP is supported by an Australian National Health and Medical Research Council Early Career Fellowship (1088535). MR is partially funded by the Spanish Health Services Research on Chronic Patients Network (REDISSEC)/Institute of Health Carlos III. The views expressed in this article are the views of the authors and may not be understood or quoted as being made on behalf of, or reflecting the position of, the funder(s) or any institution.es_ES
dc.format.extent8 p.es_ES
dc.language.isoenges_ES
dc.publisherBioMed Centrales_ES
dc.rightsAttribution 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceSyst Rev. 2017 Apr 4;6(1):69es_ES
dc.subject.otherAutism spectrum disorderses_ES
dc.subject.otherCanceres_ES
dc.subject.otherCentral Nervous System Disorderes_ES
dc.subject.otherAlzheimer’s Diseasees_ES
dc.subject.otherAnorexia Nervosaes_ES
dc.subject.otherAmyotrophic Lateral Sclerosises_ES
dc.subject.otherAutism Spectrum Disorderses_ES
dc.subject.otherBipolar Disorderes_ES
dc.subject.otherDepressiones_ES
dc.subject.otherDown’s Syndromees_ES
dc.subject.otherEpilepsyes_ES
dc.subject.otherHuntington’s Diseasees_ES
dc.subject.otherMultiple Sclerosises_ES
dc.subject.otherParkinson’s Diseasees_ES
dc.subject.otherSchizophreniaes_ES
dc.subject.otherSystematic Reviewes_ES
dc.subject.otherMeta-Analysises_ES
dc.titleCancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://dx.doi.org/10.1186/s13643-017-0466-yes_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1186/s13643-017-0466-y
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International